Acutaas Chemicals Reports Strong Q1 FY27 Results with Revenue Up 59.1% and PAT Rising 70.4%

Acutaas Chemicals Reports Strong Q1 FY27 Results with Revenue Up 59.1% and PAT Rising 70.4%​

Surat, July 24, 2026: Acutaas Chemicals Limited, a global manufacturer of advanced pharmaceutical intermediates and specialty chemicals, announced its consolidated financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ended June 30, 2026. The company reported significant growth across key metrics, with revenue from operations increasing by 59.1% year-over-year (YoY).

The financial performance highlights the company's strong market position and operational agility. Q1 FY27 saw Revenue from Operations stand at Rs. 3,297 million (mn), up 59.1% compared to Q1 FY26, which recorded revenue of Rs. 2,072 mn. Gross Profit reached Rs. 1,909 mn, reflecting a 73.0% YoY increase.

The company maintained robust margins, with the Gross Margin reaching 57.9%. EBITDA for the quarter was Rs. 1,131 mn, marking a significant rise of 122.1% over the Rs. 509 mn recorded in Q1 FY26. The corresponding EBITDA Margin stood at 34.3%, compared to 24.6% in the previous year.

Net Profit After Tax (PAT) for Q1 FY27 was Rs. 750 mn, showing a 70.4% increase from the Rs. 440 mn reported in Q1 FY26. This growth propelled the PAT Margin to 22.7%, up 151 basis points (bps) YoY.

Financial details comparing Q1 FY27 against previous periods are presented below:

Operational Highlights and Future Outlook​

Mr. Naresh Patel, Executive Chairman and Managing Director of Acutaas Chemicals Limited, commented on the results, stating that the company started the year strongly. He credited the growth to the agility of the business model and the ability to consistently deliver products to customers without compromise.

Patel also noted external recognitions achieved by the company, including certification as a Great Place to Work—a recognition validating the team culture built on trust and collaboration. Furthermore, Acutaas received the Responsible Care certification from the Indian Chemical Council, reaffirming its commitment to sustainable and responsible growth according to industry standards.

Looking ahead, the management expressed confidence in achieving 25% revenue growth for the full fiscal year while maintaining stable margins.

Acutaas Chemicals Limited operates as a specialty chemicals manufacturer serving various industries such as pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. The company's core strength lies in research-driven development of advanced pharmaceutical intermediates used for both regulated and generic APIs, alongside intermediates for New Chemical Entities (NCEs). Acutaas is also expanding its portfolio to include high-value specialty chemicals tailored for emerging technologies like battery materials and next generation electronic applications.

ACUTAAS Stock Price Movement​

As of 1:11 PM, shares of Acutaas Chemicals Limited are slipping by 5.50% in live trading, with the stock currently holding at ₹3268.9. The company has traded a volume of 607,485 shares during the session as the equity sheds nearly ₹190.20 intraday.